Detalhe da pesquisa
1.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Am J Hematol
; 98(4): 645-657, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606708
2.
Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.
Cancer Immunol Immunother
; 71(1): 13-24, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33993319
3.
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Blood
; 136(20): 2290-2295, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32959052
4.
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
Eur J Haematol
; 109(6): 719-727, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36048142
5.
Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
Ann Hematol
; 100(6): 1359-1376, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33796898
6.
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Eur J Haematol
; 106(4): 574-583, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512026
7.
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Blood
; 131(17): 1955-1959, 2018 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29437588
8.
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.
Haematologica
; 105(2): 478-489, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171644
9.
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II result.
Eur J Haematol
; 104(4): 281-290, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838764
10.
Crystal-storing lymphocytosis.
Am J Hematol
; 99(1): 142-143, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37161841
11.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Invest New Drugs
; 36(1): 62-74, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597151
12.
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia FLT3-ITD patients.
Haematologica
; 108(9): 2531-2534, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794507
13.
Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).
Haematologica
; 108(6): 1691-1696, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546425
14.
Ibrutinib-Induced Neutrophilic Dermatosis.
Am J Dermatopathol
; 40(3): 198-200, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473834
15.
More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.
N Engl J Med
; 380(7): 696, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30785715
16.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Haematologica
; 107(8): 1928-1932, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320922
17.
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.
Eur J Nucl Med Mol Imaging
; 44(12): 2018-2024, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634685
18.
Plasma cell dedifferentiation in refractory multiple myeloma.
Br J Haematol
; 193(2): 212, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772753
19.
Secondary haemophagocytic lymphohistiocytosis is a rare occurrence amongst cancer patients with COVID-19.
Br J Haematol
; 192(3): e87-e90, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326597
20.
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Haematologica
; 101(4): 474-81, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26721893